These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 10330975)

  • 1. Transplantation of cells and tissues expressing Fas ligand.
    Duke RC; Newell E; Schleicher M; Meech S; Bellgrau D
    Transplant Proc; 1999 May; 31(3):1479-81. PubMed ID: 10330975
    [No Abstract]   [Full Text] [Related]  

  • 2. On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.
    Greil R; Egle A; Villunger A
    Leuk Lymphoma; 1998 Nov; 31(5-6):477-90. PubMed ID: 9922038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction.
    Kang SM; Schneider DB; Lin Z; Hanahan D; Dichek DA; Stock PG; Baekkeskov S
    Nat Med; 1997 Jul; 3(7):738-43. PubMed ID: 9212099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fas (CD95/Apo-1) ligand regulation in T cell homeostasis, cell-mediated cytotoxicity and immune pathology.
    Brunner T; Wasem C; Torgler R; Cima I; Jakob S; Corazza N
    Semin Immunol; 2003 Jun; 15(3):167-76. PubMed ID: 14563115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cloning and potential utility of porcine Fas ligand: overexpression in porcine endothelial cells protects them from attack by human cytolytic cells.
    Tsuyuki S; Kono M; Bloom ET
    Xenotransplantation; 2002 Nov; 9(6):410-21. PubMed ID: 12371937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Fas/Fasl in Kupffer cell-dependent deletion of alloantigen activated T cells following liver transplantation.
    Sun Z; Wada T; Uchikura K; Ceppa E; Klein AS
    Transplant Proc; 2001; 33(1-2):279-82. PubMed ID: 11266819
    [No Abstract]   [Full Text] [Related]  

  • 7. Fas and Fas ligand in discordant xenogeneic antibody-dependent cell-mediated cytotoxicity.
    Fujiwara I; Nakajima H; Matsuda T; Mizuta N; Yamagishi H; Oka T
    Transplant Proc; 1998 Aug; 30(5):2488-90. PubMed ID: 9723550
    [No Abstract]   [Full Text] [Related]  

  • 8. Immunology. Ways around rejection.
    Vaux DL
    Nature; 1995 Oct; 377(6550):576-7. PubMed ID: 7566165
    [No Abstract]   [Full Text] [Related]  

  • 9. Mechanisms of rejection of nonvascularized grafts: the role of perforin and Fas.
    Selvaggi G; Ricordi C; Podack E; Inverardi L
    Transplant Proc; 1997 Jun; 29(4):2075-6. PubMed ID: 9193534
    [No Abstract]   [Full Text] [Related]  

  • 10. Overexpression of Fas ligand does not confer immune privilege to a pancreatic beta tumor cell line (betaTC-3).
    Okamoto S; Takamizawa S; Bishop W; Wen J; Kimura K; Sandler A
    J Surg Res; 1999 Jun; 84(1):77-81. PubMed ID: 10334893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Murine xenogeneic immune responses to the human testis: a presumed immune-privileged tissue.
    Kimmel SG; Ohbatake M; Kushida M; Merguerian P; Clarke ID; Kim PC
    Transplantation; 2000 Mar; 69(6):1075-84. PubMed ID: 10762210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Negative regulation of CD95 ligand gene expression by vitamin D3 in T lymphocytes.
    Cippitelli M; Fionda C; Di Bona D; Di Rosa F; Lupo A; Piccoli M; Frati L; Santoni A
    J Immunol; 2002 Feb; 168(3):1154-66. PubMed ID: 11801650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunosensitization of prostate carcinoma cell lines for lymphocytes (CTL, TIL, LAK)-mediated apoptosis via the Fas-Fas-ligand pathway of cytotoxicity.
    Frost P; Ng CP; Belldegrun A; Bonavida B
    Cell Immunol; 1997 Aug; 180(1):70-83. PubMed ID: 9316641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Downregulation of Fas ligand by shedding.
    Tanaka M; Itai T; Adachi M; Nagata S
    Nat Med; 1998 Jan; 4(1):31-6. PubMed ID: 9427603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic effects on the inhibition of human CD8+ cytotoxic T lymphocytes-mediated killing against xenograft cells by coexpression of membrane-bound Human FasL and decoy Fas antigen.
    Tanemura M; Kawamoto K; Ito T; Uchikoshi F; Shimada K; Nishida T; Matsuda H
    Transplant Proc; 2005 Dec; 37(10):4607-9. PubMed ID: 16387181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD95 ligand in graft rejection.
    Yagita H; Seino K; Kayagaki N; Okumura K
    Nature; 1996 Feb; 379(6567):682. PubMed ID: 8602212
    [No Abstract]   [Full Text] [Related]  

  • 17. T cell dependent and independent antitumor immunity generated by the expression of Fas ligand on mouse lung carcinoma cells.
    Tada Y; O-Wang J; Takiguchi Y; Tatsumi K; Kuriyama T; Tagawa M
    Int J Mol Med; 2002 Mar; 9(3):281-5. PubMed ID: 11836634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of biochemical and biological functions of Fas-ligand (FasL) and Fas on activated T cells in allo-immune response.
    Nakajima H; Oka T
    Transplant Proc; 1997; 29(1-2):1096-100. PubMed ID: 9123217
    [No Abstract]   [Full Text] [Related]  

  • 19. Human Fas-ligand expression on porcine endothelial cells does not protect against xenogeneic natural killer cytotoxicity.
    Matter-Reissmann UB; Sonntag KC; Gilli UO; Leguern C; Schneider MK; Seebach JD
    Xenotransplantation; 2004 Jan; 11(1):43-52. PubMed ID: 14962292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperthermia enhances CD95-ligand gene expression in T lymphocytes.
    Cippitelli M; Fionda C; Di Bona D; Piccoli M; Frati L; Santoni A
    J Immunol; 2005 Jan; 174(1):223-32. PubMed ID: 15611244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.